TY - JOUR
T1 - A) Successful MARS treatment in severe cholestatic patients with acute on chronic liver failure.
AU - Di Campli, Cristiana
AU - Gaspari, Rita
AU - Mignani, Vittorio
AU - Stifano, Giovanna
AU - Santoliquido, Angelo
AU - Zileri Dal Verme, Lorenzo
AU - Proietti, Rodolfo
AU - Pola, Paolo
AU - Gentiloni Silveri, Nicolo'
AU - Gasbarrini, Giovanni Battista
AU - Gasbarrini, Antonio
PY - 2003
Y1 - 2003
N2 - Extracorporeal liver devices have gained great attention as a complementary approach to liver transplantation in patients with acute on chronic liver failure. Among others, Molecular Adsorbent Recycling System (MARS) is a hemodiafiltration against albumin able to remove low molecular weight toxins. We aimed to validate the use of MARS in patients presenting with acute on chronic liver failure with severe cholestasis. We enrolled 7 patients with acute on chronic liver failure, presenting with bilirubin >25 mg/dl and hepatorenal syndrome and/or hepatic encephalopathy grade >II. Liver biochemistry, coagulation, blood cell count, electrolytes, ammonia, lactate, blood urea nitrogen, creatinine, bile acids, Fischer ratio, and encephalopathy grade were assessed before and after each MARS treatment. MARS can represent a safe therapeutic choice to achieve a quick improvement of neurological status, a hemodynamic stability, and a better clinical outcome. In particular, our encouraging results suggest that also, patients with severe cholestasis may represent in the future a good indication for MARS treatment.
AB - Extracorporeal liver devices have gained great attention as a complementary approach to liver transplantation in patients with acute on chronic liver failure. Among others, Molecular Adsorbent Recycling System (MARS) is a hemodiafiltration against albumin able to remove low molecular weight toxins. We aimed to validate the use of MARS in patients presenting with acute on chronic liver failure with severe cholestasis. We enrolled 7 patients with acute on chronic liver failure, presenting with bilirubin >25 mg/dl and hepatorenal syndrome and/or hepatic encephalopathy grade >II. Liver biochemistry, coagulation, blood cell count, electrolytes, ammonia, lactate, blood urea nitrogen, creatinine, bile acids, Fischer ratio, and encephalopathy grade were assessed before and after each MARS treatment. MARS can represent a safe therapeutic choice to achieve a quick improvement of neurological status, a hemodynamic stability, and a better clinical outcome. In particular, our encouraging results suggest that also, patients with severe cholestasis may represent in the future a good indication for MARS treatment.
KW - MARS
KW - cholestatic
KW - MARS
KW - cholestatic
UR - http://hdl.handle.net/10807/20740
M3 - Article
SN - 0160-564X
SP - 565
EP - 569
JO - Artificial Organs
JF - Artificial Organs
ER -